Alcyone Lifesciences, Inc., a Concord, Massachusetts-based medical device company developing products for the treatment of difficult neuropathological conditions, closed a $4m Series B financing.
The round was led by Edgar D. Jannotta Jr., (who is also a member of the Board of Director) with participation from Harbor Light Capital Partners.
The company intends to use the funds for further development of its platform technology for delivery of therapy to the brain as well as a novel technology to manage CSF (cerebrospinal fluid) shunt occlusions.
Alcyone Lifesciences was founded in 2010 by PJ Anand, CEO, Adam Fleisher, MD., Associate Professor of Neuroscience, UCSD, Banner Alzheimer’s Institute, and William Olbricht, PhD, Professor of Biomedical Engineering, Cornell University.
FinSMEs
15/01/2014